Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNT1 | Q5JUK3 | 10/20 | 0.48 |
| ▸ | KCNQ1 | P51787 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.48 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.48 |
| ▸ | KCNMB1 | Q16558 | 1/20 | 0.48 |
| ▸ | KCNT2 | Q6UVM3 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PPARD | Q03181 | 4/20 | 0.45 |
| ▸ | PPARA | Q07869 | 4/20 | 0.45 |
| ▸ | ACACB | O00763 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24660721 | 0.89 | KCNT1 (0.59) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660575 | 0.89 | KCNT1 (0.59) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL22637519 | 0.89 | KCNT1 (0.59) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660775 | 0.87 | KCNT1 (0.61) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660613 | 0.87 | KCNT1 (0.61) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660470 | 0.87 | KCNT1 (0.61) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660468 | 0.87 | KCNT1 (0.60) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660631 | 0.86 | KCNT1 (0.66) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660189 | 0.86 | KCNT1 (0.66) | KCNT1KCNQ1KCNH2CACNA1CSCN5A | |
| SCHEMBL24660486 | 0.86 | KCNT1 (0.51) | KCNT1KCNQ1KCNH2CACNA1CSCN5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | PRAXIS PRECISION MEDICINES, INC. (US) | 2022-08-18 | — | — | US | disclosed |
| EP-3962481-A1 | KCNT1 INHIBITORS AND METHODS OF USE | Praxis Precision Medicines, Inc. (US) | 2022-03-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220259193-A1 | KCNT1 INHIBITORS AND METHODS OF USE | KCNT1, KCNT2, KCNQ2 | KCNT1 1/4885KCNQ1 4/4885KCNH2 33/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.